TissueTech

TissueTech

Founded in 2001 by Amy Tseng, President and CEO, and Dr. Scheffer Tseng, Chairman and Chief Scientific Officer, TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in ophthalmology, optometry, orthopedics and wound care. The Company has pioneered stem cell research using human amniotic membrane to treat corneal surface conditions and developed Amniograft™, the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation. The National Institute of Health (NIH) has supported TissueTech’s research with more than 25 continuous years of research grants. Since inception, 130,000 human implants have been conducted using the Company’s patented Crotek™ process and 300 peer-reviewed scientific publications have been produced supporting the technology platform.

News

AMNIOX Highlights Study Demonstrating Improved Outcomes in Patients Treated with CLARIX® Regenerative Matrix as an Adjunct to Lumbar Discectomy

AMNIOX Medical, Inc., a TissueTech™, Inc., company, announced the results of a prospective randomized clinical study of its proprietary cryopreserved Amniotic Membrane (AM) as an adjunct to lumbar discectomy. The findings will be presented at the North American Spine Society 2016 Annual Meeting, by the study’s lead investigator, D. Greg Anderson, M.D. of the Rothman […]

Navigating the Value Analysis Committee

To provide medical device and technology companies with a greater perspective on successfully navigating VACs, we spoke with four River Cities’ med tech portfolio companies that have dedicated countless hours to mastering the pathway to get innovative products in front of and approved by these ever-vigilant committees.

TissueTech Highlights Clinical Experience Showing In-Utero Spina Bifida Repair with NEOX® Wound Allograft

“Doctors continue to lead the innovation driving our discovery of the full healing potential of cryopreserved umbilical cord tissue.”

Amniox Medical Touts Reimbursement Win

NEOX® Wound Allograft accessible to more than 4.4 Million additional medicare lives.

AMNIOX Highlights Study Showing More Than Eighty Seven Percent of Patients With Diabetic Foot Ulcers Achieve Healing When Treated with NEOX® Wound Allograft

Amniox highlights study showing more than 87% of patients with diabetic foot ulcers achieve healing when treated with NEOX® Wound Allograft.

Page 1 of 3123

Status

Active

Fund

River Cities Fund V

Year Invested

2013

City and State

Doral, FL; Atlanta, GA

Portfolio Manager

Carter McNabb